Pharmaceutical

Merck and AstraZeneca receive approval for Lynparza in Japan

Merck (MSD) and AstraZeneca have received approval in Japan for Lynparza to treat BRCA-mutated (BRCAm) castration-resistant prostate cancer.

Aug 26, 2023 - 20:00
Merck and AstraZeneca receive approval for Lynparza in Japan
Merck (MSD) and AstraZeneca have received approval in Japan for Lynparza to treat BRCA-mutated (BRCAm) castration-resistant prostate cancer.
Read the original article

Tags:

Previous Article

Five ways to build trust in patient data sharing

Next Article

FDA Panel’s Divided Verdict Delays Approval for Medtronic’s Blood Pressure Device

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

U.S. government spent more on health care in 2022 than six countries with universal health care combined

U.S. government spent more on health care in 2022 than ...

Dec 19, 2023

Leading innovators in anti-inflammatory anaesthetics for the pharmaceutical industry

Leading innovators in anti-inflammatory anaesthetics fo...

May 8, 2023

Opinion: The definition of clinical trial diversity must include disabled people

Opinion: The definition of clinical trial diversity mus...

Aug 17, 2023